DarioHealth (DRIO) CEO Reports 60,000 Share Award; Ownership 156,853

Rhea-AI Filing Summary

Raphael Erez, who is listed as Chief Executive Officer and a director of DarioHealth Corp. (DRIO), reported a non‑derivative award on this Form 4. On 09/11/2025 he was granted 60,000 restricted shares at a stated price of $0; the award vests in two equal installments on the last day of each successive annual anniversary over a two‑year period. Following the grant and reflecting a 20‑for‑1 reverse stock split effected August 28, 2025, the filing reports total beneficial ownership of 156,853 common shares. The filing also discloses indirect ownership of 1,894 shares through Dicilyon Consulting and Investment Ltd. The report is signed by Mr. Erez on 09/15/2025.

Positive

• CEO equity grant disclosed (60,000 restricted shares) with clear vesting schedule
• Post‑transaction beneficial ownership reported as 156,853 shares, including reverse split adjustment
• Indirect holdings disclosed (1,894 shares via Dicilyon Consulting and Investment Ltd.) enhancing transparency

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO received a time‑based restricted share award of 60,000 shares; ownership totals 156,853 shares after the reverse split.

The award is a standard executive equity grant with a two‑year annual vesting schedule, recorded at a $0 per‑share grant price consistent with restricted share awards rather than open‑market purchases. The filing clarifies post‑split share counts by noting the 20‑for‑1 reverse split on August 28, 2025, which is important for accurately tracking ownership percentages. Indirect holdings via Dicilyon Consulting and Investment Ltd. are disclosed separately, adding transparency to total beneficial ownership.

Corporate Governance Expert

TL;DR: Disclosure is clear and routine: time‑based restricted shares granted to the CEO with appropriate vesting details and indirect ownership noted.

The Form 4 provides the necessary elements for Section 16 reporting: grant date, number of shares, vesting schedule, and post‑transaction beneficial ownership. The explicit note regarding the reverse split helps prevent misinterpretation of reported share counts. There are no other governance events or departures disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Raphael Erez

(Last) (First) (Middle)

322 W 57TH STREET, #33B

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DarioHealth Corp. [ DRIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025(1)		A		60,000	A	$0	156,853(2)	D
Common Stock								1,894(2)	I	By Dicilyon Consulting and Investment Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period.

2. The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

	/s/ Erez Raphael	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DarioHealth (DRIO) CEO Raphael Erez report on Form 4?

He reported a grant of 60,000 restricted common shares on 09/11/2025 and listed total beneficial ownership of 156,853 shares following the transaction.

When do the restricted shares granted to Raphael Erez vest?

The restricted award vests in two equal installments on the last day of each successive annual anniversary after the grant date over a two‑year period.

Was a reverse stock split disclosed in the Form 4 for DRIO?

Yes. The filing states the reported share counts reflect a 20‑for‑1 reverse stock split effected on August 28, 2025.

Does Raphael Erez hold any shares indirectly according to the filing?

Yes. The filing discloses indirect ownership of 1,894 shares through Dicilyon Consulting and Investment Ltd.

What price was reported for the restricted share award?

The reported price is $0, indicating a restricted share grant rather than a market purchase.